As such, our studies provide a mechanistic explanation for the hepatoprotective effects of FGF21 analogues in recent clinical trials including reduction in steatosis (Sanyal et al., 2019; Harrison et al., 2021; Luo et al., 2022) as well as the fibrotic marker N-terminal type III collagen pro-peptide (Sanyal et al., 2019; Harrison et al., 2021), and further highlight the potential of FGF21 for clinical implementation as a therapeutic in the treatment of advanced NASH. Here, FGF21 is linked to steatosis.